Financials data is unavailable for this security.
View more
Year on year Myriad Genetics Inc had net income fall 135.09% from a loss of 112.00m to a larger loss of 263.30m despite a 11.03% increase in revenues from 678.40m to 753.20m. An increase in the cost of goods sold as a percentage of sales from 29.78% to 31.36% was a component in the falling net income despite rising revenues.
| Gross margin | 69.15% |
|---|---|
| Net profit margin | -14.08% |
| Operating margin | -14.06% |
| Return on assets | -10.40% |
|---|---|
| Return on equity | -16.39% |
| Return on investment | -12.43% |
More ▼
Cash flow in USDView more
In 2023, Myriad Genetics Inc increased its cash reserves by 112.20%, or 74.50m. Cash Flow from Financing totalled 152.90m or 20.30% of revenues. In addition the company used 110.90m for operations while cash from investing totalled 31.90m.
| Cash flow per share | -0.6082 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.04 |
|---|---|
| Tangible book value per share | 1.46 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.90 |
|---|---|
| Quick ratio | 1.73 |
| Total debt/total equity | 0.0533 |
|---|---|
| Total debt/total capital | 0.0506 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -128.84%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 61.39 |
